1-7 of 7
Keywords: Paclitaxel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

Available to Purchase
Subject Area:
Oncology
Ali O. Kaya, Ugur Coskun, Metin Ozkan, Alper Sevinc, Ahmet U. Yilmaz, Mahmut Gumus, Olcun U. Unal, Nuriye Y. Ozdemir, Suleyman Alici, Veli Berk, Hatice Degerli, Mehmet K. Oner, Cemil Ozturk, Umut Kefeli, Celalettin Camcı, for the Anatolian Society of Medical Oncology (ASMO)
Journal: Onkologie
Onkologie (2012) 35 (10): 576–580.
https://doi.org/10.1159/000342674
Published Online: 18 September 2012
... retrospectively evaluated the efficacy and toxicity of paclitaxel plus doxorubicin as a second-line treatment in patients with urothelial carcinoma, who had not responded to a prior platinum plus gemcitabine combination. Patients and Methods: All patients received intravenous infusions of paclitaxel (175 mg/m 2...
View articletitled, Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy
Open the PDF for Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy in another window
Journal Articles

Favorable Response of Heavily Treated Wilms’ Tumor to Paclitaxel and Carboplatin

Available to Purchase
Subject Area:
Oncology
Saeko Ozaki, Nagio Takigawa, Eiki Ichihara, Katsuyuki Hotta, Isao Oze, Etsuko Kurimoto, Soichiro Fushimi, Tetsuya Ogino, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Onkologie
Onkologie (2012) 35 (5): 283–286.
https://doi.org/10.1159/000338532
Published Online: 24 April 2012
...Saeko Ozaki; Nagio Takigawa; Eiki Ichihara; Katsuyuki Hotta; Isao Oze; Etsuko Kurimoto; Soichiro Fushimi; Tetsuya Ogino; Masahiro Tabata; Mitsune Tanimoto; Katsuyuki Kiura Background: Heavily treated Wilms’ tumor responding to the combination of paclitaxel and carboplatin has not yet been reported...
View articletitled, Favorable Response of Heavily Treated Wilms’ Tumor to Paclitaxel and Carboplatin
Open the PDF for Favorable Response of Heavily Treated Wilms’ Tumor to Paclitaxel and Carboplatin in another window
Journal Articles

The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer

Available to Purchase
Subject Area:
Oncology
Takaya Shimura, Mika Kitagawa, Tomonori Yamada, Michihiro Yoshida, Masahide Ebi, Yoshikazu Hirata, Takashi Mizushima, Tsutomu Mizoshita, Satoshi Tanida, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Journal: Onkologie
Onkologie (2012) 35 (4): 176–183.
https://doi.org/10.1159/000337400
Published Online: 15 March 2012
...Takaya Shimura; Mika Kitagawa; Tomonori Yamada; Michihiro Yoshida; Masahide Ebi; Yoshikazu Hirata; Takashi Mizushima; Tsutomu Mizoshita; Satoshi Tanida; Hiromi Kataoka; Takeshi Kamiya; Takashi Joh Background: Paclitaxel and docetaxel show similar anticancer mechanisms, but cross-resistance...
View articletitled, The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer
Open the PDF for The Impact of Cross-Resistance Between Paclitaxel and Docetaxel for Metastatic Gastric Cancer in another window
Journal Articles

Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors

Available to Purchase
Subject Area:
Oncology
Silvia Park, Soohyeon Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Won Ki Kang, Young Suk Park, Ho Yeong Lim
Journal: Onkologie
Onkologie (2011) 34 (8-9): 416–420.
https://doi.org/10.1159/000331129
Published Online: 23 August 2011
...Silvia Park; Soohyeon Lee; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Won Ki Kang; Young Suk Park; Ho Yeong Lim Background: In relapsed germ cell tumors, salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) is a well-established regimen for patients with favorable features...
View articletitled, Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors
Open the PDF for Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors in another window
Journal Articles

Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial

Available to Purchase
Subject Area:
Oncology
Jacek Jassem, Tadeusz Pienkowski, Anna Pluzanska, Svetislav Jelic, Vera Gorbunova, Juris Berzins, Thomas Nagykalnai, Laura Biganzoli, Alessandra Aloe, Ludovic Astier, Stephane Munier
Journal: Onkologie
Onkologie (2009) 32 (8-9): 468–472.
https://doi.org/10.1159/000226210
Published Online: 20 July 2009
... the efficacy difference observed in a phase III randomised clinical trial that compared doxorubicin plus paclitaxel (AT) versus fluorouracil/doxorubicin/cyclophosphamide (FAC) in first-line chemotherapy of metastatic breast cancer was maintained after a longer follow-up period. Material and Methods: A blinded...
View articletitled, Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial
Open the PDF for Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial in another window
Journal Articles

Concurrent Chemoradiotherapy with Weekly Paclitaxel in Malignant Cerebral Glioma Treatment

Available to Purchase
Subject Area:
Oncology
José Paulo Montemor, Fernanda Maris Peria, Carlos Roberto Monti, Luis Salvador Petrilli, Benedicto Oscar Colli, Carlos Gilberto Carlotti Júnior
Journal: Onkologie
Onkologie (2008) 31 (8-9): 435–439.
https://doi.org/10.1159/000141517
Published Online: 21 August 2008
... treatments, they still have an adverse prognosis. Paclitaxel is a cytotoxic agent with radiosensitizing properties and exerts objective growth inhibition in glioma tumor cells. Patients and Methods: From 1998 to 2002, 61 microneurosurgically treated patients were randomized to group I (18 GB, 14 AA) which...
View articletitled, Concurrent Chemoradiotherapy with Weekly Paclitaxel in Malignant Cerebral Glioma Treatment
Open the PDF for Concurrent Chemoradiotherapy with Weekly Paclitaxel in Malignant Cerebral Glioma Treatment in another window
Journal Articles

Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-Up

Available to Purchase
Subject Area:
Oncology
Franz G. Bader, Florian Lordick, Ulrich Fink, Karen Becker, Heinz Höfler, Raymonde Busch, Jörg R. Siewert, Katja Ott
Journal: Onkologie
Onkologie (2008) 31 (7): 366–372.
https://doi.org/10.1159/000135515
Published Online: 16 June 2008
...Franz G. Bader; Florian Lordick; Ulrich Fink; Karen Becker; Heinz Höfler; Raymonde Busch; Jörg R. Siewert; Katja Ott Introduction: We report a comparative analysis of 2 sequential, prospective phase II trials on the efficacy of platinum/leucovorin/5-fluorouracil (PLF) +/– paclitaxel (T-PLF...
View articletitled, Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-Up
Open the PDF for Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-Up in another window